Medicaid spending on Applied Behavior Analysis (ABA) therapy for children with autism has surged past $5.15 billion between 2018 and 2024, a period marked by increasing federal and state efforts to combat fraud and ensure accountability in the program. ABA therapy, a critical intervention for hundreds of thousands of families, aims to help children with autism develop essential communication, social, and daily living skills through structured, one-on-one sessions.
The significant increase in Medicaid disbursements for ABA therapy has drawn heightened attention from regulators and prosecutors. In May, federal authorities in Minnesota charged two autism clinic operators with allegedly defrauding Medicaid of $46.6 million for services that were deemed unnecessary or never provided, including claims linked to fabricated autism diagnoses. This action followed a separate case earlier this year where a Minnesota woman pleaded guilty to participating in a $14 million Medicaid autism fraud scheme.
Investigations by The Wall Street Journal and The New York Times have also revealed allegations of providers billing for services not rendered, exaggerating therapy hours, and rapidly expanding their operations amid the surge in Medicaid funding. The Centers for Medicare & Medicaid Services (CMS) acknowledged observing substantial growth in ABA therapy spending and emphasized the importance of ensuring services are clinically appropriate, delivered by qualified professionals, and protected by robust program integrity measures.
Some providers have received unusually large Medicaid reimbursements under the primary ABA billing code, with some claims potentially equating to hundreds of dollars per minute of therapy, based on standard billing units. While these high payment amounts do not automatically indicate fraud and can stem from administrative factors, they have contributed to increased scrutiny.
Responses to these concerns vary among states. Republican-led states like Florida have prioritized stricter fraud enforcement and oversight. Over the past year, Florida reported recovering more than $72 million in improper Medicaid payments and barred hundreds of behavior analysts from participating in the program due to fraud allegations. In a broader move, Florida Governor Ron DeSantis launched a statewide Medicaid Integrity Initiative aimed at enhancing provider screening, fraud detection, and oversight.
In contrast, Georgia lawmakers have focused on reimbursement rates. Recent legislative discussions have involved a Medicaid managed care organization's decision to reduce ABA reimbursement rates by 20%, despite industry reports of a more than 300% increase in the utilization of autism therapy services. This divergence highlights the ongoing challenge of balancing the need to prevent fraud with ensuring continued access to vital therapies for children with autism.
The Trump administration has identified the elimination of fraud, waste, and abuse across federal programs, including Medicaid, as a key policy priority. Supporters of enhanced oversight argue that every dollar lost to fraud represents a diversion of resources that could otherwise fund essential care for vulnerable populations dependent on the Medicaid safety net. The surge in spending and the concurrent rise in fraud investigations underscore the complex interplay between program expansion, provider oversight, and taxpayer protection in the delivery of autism therapies.